

CLARIFICATION TO CERTAIN MEDIA REPORTS

1. Introduction

The Board of Directors ("**Board**") of Cordlife Group Limited (the "**Company**") refers to:

- (a) its announcements dated 30 November 2023, 13 December 2023, 15 December 2023, 17 January 2024, 23 January 2024, 8 April 2024, 28 May 2024, 18 June 2024, 30 August 2024, 6 September 2024, 13 September 2024, 1 October 2024 and 14 January 2025 relating to, *inter alia*, the renewal by the Ministry of Health ("**MOH**") of the Company's cord blood banking service licence (the "**CBBS Licence**") and human tissue banking service licence for a period of one (1) year with effect from 14 January 2025;
- (b) its announcements dated 8 April 2024, 25 March 2025, 2 April 2025 and 14 May 2025 relating to, *inter alia*, the Company sending over 200 samples of donated cord blood units ("**CBUs**") from the five (5) cryogenic storage tanks under investigation by the MOH which were found to be at low risk of being adversely affected by temperature excursions for testing across multiple third-party laboratories ("**Relevant Tanks**");
- (c) the press release issued on 29 September 2025 by MOH on the foregoing ("**MOH Release**");
- (d) its announcement dated 1 October 2025 (the "**MOH Notice Announcement**") relating to, *inter alia*, the receipt by the Company of a letter from the MOH of the Director-General of Health's intention to suspend the Company's CBBS Licence for a period of one (1) year (the "**MOH Notice**");
- (e) certain media articles relating to the MOH Release (collectively, the "**Media Articles**"); and
- (f) its announcement dated 13 October 2025 relating to, *inter alia*, the extension of time granted by MOH to the Company to provide written representations in relation to the contents of the MOH Notice.

Unless defined, all capitalised terms used and not defined in this announcement shall have the same meanings as defined in the MOH Notice Announcement.

2. Inaccuracies in the Media Articles

The Company notes the contents of the Media Articles in relation to matters set out in the MOH Release, and has observed that the Media Articles contain inaccuracies pertaining to and/or arising out of: (i) the effect of the MOH Notice served on the Company; and (ii) the number of CBUs affected by any process failures identified by MOH.

The relevant extracts from the Media Articles are set out below, with the Company's clarifications:

(a) New CBUs Collected since 14 January 2025

Several of the Media Articles reported that there were process failures in the collection, processing and testing of approximately 160 CBUs that the Company had collected since January 2025.

Company's clarification:

The Company wishes to clarify that while the MOH Release did state that approximately 160 CBUs had been collected by the Company since the resumption of its cord blood banking services in January 2025, it did **not** state that 160 CBUs were affected by the process failures which had been identified by MOH.

Instead, as stated in the MOH Notice Announcement, in the MOH Notice, the Director-General of Health intends to direct the Company to, *inter alia*, retrospectively review all CBUs collected since 14 January 2025 against the Company's established policies to identify and resolve any deviations. If there are instances of non-conformance, the Company is required to disclose such instances to the client who shall be counselled by a qualified haematologist on the implications of non-conformance in clinical use.

The Company would like to assure its customers and shareholders that the Company, together with its technical team advisers, has commenced a review on the CBUs collected since 14 January 2025, and will provide a further update in due course.

(b) Effect of the MOH Notice

Of the Media Articles, several reported that the Company would be given 14 days to submit its written representations to MOH, failing which its CBBS License would automatically be suspended.

Company's clarifications:

The Company wishes to clarify that although the MOH Notice allows 14 days for the Company to respond to the MOH Notice, any such suspension would only take effect upon the service of a subsequent notice of decision by MOH, and upon consideration of the representations by Cordlife (if any).

As announced by the Company on 13 October 2025, the Company has been granted an extension of time from 13 October 2025 to **27 October 2025** to submit its written representations in relation to the contents of the MOH Notice to the Director-General of Health. The Company is continuing to seek advice on the appropriate response to the MOH Notice and will provide an update in due course.

3. Test Results for Remaining 3 Tanks Not Relating to A New Incident

It is relevant to highlight that the tested samples from the Remaining 3 Tanks, which did not meet the criteria for viability and potency came from the Remaining 3 Tanks, related to the 200 sample CBUs from the Relevant Tanks which were sent for testing sometime around April 2024 (as announced by the Company on 8 April 2024).

The failure of the certain tested samples from the Remaining 3 Tanks to meet the criteria for viability and potency was not a result of a new lapse/incident where the Company's cryogenic storage tanks were exposed to temperatures outside of their normal temperature range. It is a follow-on update of the ongoing investigation on the Additional Relevant Tank Test Results (as announced by the Company on 8 April 2024).

As mentioned in the MOH Notice Announcement, the Company will, together with its technical team and advisers, conduct a full investigation on the Additional Relevant Tank Test Results for the Remaining 3 Tanks. Pending completion of such investigations, the Company is unable to ascertain whether the Remaining 3 Tanks were affected by temperature excursions.

4. Cautionary Statement

The Company will update its shareholders if there are any material developments in relation to the above, in accordance with the requirements of the SGX-ST listing rules.

In the meantime, shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company. They should consult their stockbrokers, bank managers, solicitors, or other professional advisers if they have any doubt about the action they should take.

By order of the Board

CORDLIFE GROUP LIMITED

Cheok Hui Yee
Goh Xun Er
Company Secretaries

21 October 2025